A Study Evaluating the Safety, Tolerability, and Activity of ICM-203 in Subjects With Knee Osteoarthritis.

Starting soon · Phase 1/Phase 2

Conditions studied: Osteoarthritis, Knee

In brief

The purpose of this study is to determine the safety, tolerability, and activity of ICM-203, a recombinant adeno-associated viral (AAV) vector that expresses a therapeutic gene that promotes cartilage formation, reduces joint inflammation and pain, as well as improves joint physical function, by injecting escalating doses of ICM-203 into the knee of subjects with mild to moderate knee osteoarthritis (OA). Approximately 6 to 18 subjects will be enrolled into 3 successive dose-escalating groups in a 3+3 study design, whereby 3 study subjects in each group will be dosed sequentially with ICM-203 and 3 additional subjects will be dosed at the same dose level if a dose limiting toxicity (DLT) occurs in any of the first 3 subjects.

Key facts

Study ID

NCT05454566

Run by

ICM Co. Ltd.

People needed

18

Starts

2026-11-15

Expected to finish

2028-11-15

Last updated by the study team

2026-03-27

Who can join

Age: 50 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Body mass index (BMI) of 18.0 to 40.0 kg/m2, inclusive, at the time of screening.
• Kellgren-Lawrence grade 2 or grade 3 OA of target knee.
• Target knee pain between 4 and 9, inclusive, on an NRS ranging from 0 (no pain) to 10 (worst pain imaginable), at the time of screening.
• KOOS function in daily living score >25, a measure of knee function ranging from 0 (extreme problems) to 100 (no problems), at the time of screening .
• A stable treatment regimen for symptomatic relief of OA, including NSAIDs, for 4 weeks prior to screening.

You may not qualify if…

• History of rheumatoid arthritis, psoriatic arthritis, gout, pseudogout, autoimmune OA, chondrocalcinosis, hemochromatosis, villonodular synovitis, and synovial chondromatosis or other disorder that in the opinion of the Investigator could cause inflammation of the knee.
• Injection of steroid, hyaluronate or other agent, into the target knee less than 90 days prior to day 1.
• Major injury to the target knee, such as torn ligament or severe sprain, within 12 months of screening.
• Disability so severe that the subject cannot comply with the study requirements, including knee symptoms that result in significant difficulty or inability to walk.
• Surgery on the target knee within 180 days prior to day 1.
• Total knee arthroplasty or other knee surgery planned in the next 12 months.
• Active joint infection or other concurrent medical or psychiatric condition that, in the opinion of the Investigator, would make the subject unsuitable for the study.

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.